OBX-115 ORR was 67% at RP2D (n=10/15), including 2 complete responses, in patients with difficult-to-treat advanced melanoma OBX-115 safety profile remains consistent: no DLTs, no ICANS, no ICU ...
A phase II, multicenter, single-arm clinical trial of response-adapted definitive radiotherapy and cemiplimab-rwlc immunotherapy for locally advanced, unresectable cutaneous squamous cell carcinoma: ...
Oral presentation of Phase 2 results of OBX-115 in patients with advanced melanoma that has progressed following immune checkpoint inhibitor therapy from the Phase 1/2 Agni-01 multicenter study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results